Navigating 9 Analyst Ratings For United Therapeutics
Navigating 9 Analyst Ratings For United Therapeutics
瀏覽美國聯合醫療的九個分析師評級
United Therapeutics (NASDAQ:UTHR) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
聯合療法（納斯達克股票代碼：UTHR）在上個季度接受了9位分析師的分析，揭示了從看漲到看跌的一系列觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.78, a high estimate of $400.00, and a low estimate of $240.00. Observing a 13.18% increase, the current average has risen from the previous average price target of $297.56.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲336.78美元，最高估計爲400.00美元，低估值爲240.00美元。目前的平均價格上漲了13.18％，已從之前的平均目標價297.56美元上漲。
Investigating Analyst Ratings: An Elaborate Study
調查分析師評級：一項詳盡的研究
The perception of United Therapeutics by financial experts...
通過分析師最近的...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。